Background Adjunctive therapy for thrombolysis in acute myocardial infarction consists of platelet inhibition with aspirin and thrombin inhibition with heparin. Thrombin inhibition may be improved by the use of hirudin as indicated by experimental and phase II clinical studies. The randomized, double-blind phase III r-Hirudin for Improvement of Thrombolysis study (HIT III) compared a recombinant hirudin (HBW 023) with heparin. The primary end point was the incidence of death or reinfarction.
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Methods and Results Seven thousand patients with acute myocardial infarction and a duration of symptoms of less than 6 hours were to be randomized to receive intravenous heparin (70 IU/kg body wt bolus and 15 IU kg`* h-') or hirudin (0.4 mg/kg body wt bolus and 0.15 mg kg`. h-') infused over 48 to 72 hours and adjusted to an activated partial thromboplastin time of 2 to 3.5 times baseline values. In a pilot phase, 1000 patients receiving front-loaded alteplase for thrombolysis were to be recruited by 93 German centers. After enrollment of 302 patients, the trial was stopped after an increased rate of intracranial bleeding was observed in the hirudin group (5 of oronary artery reperfusion by thrombolysis in patients with acute myocardial infarction (AMI) has proved to be a major advance in cardiac medicine, leading to improvement in left ventricular ejection fraction1,2 and to a reduction in mortality.34 Nevertheless, current thrombolytic therapy is limited by the fact that despite adequate adjunctive heparin therapy, fewer than 60% of patients achieve optimal early reperfusion, and of reperfused vessels, 10% to 20% reocclude during the hospital stay.5 Both failure to achieve complete early reperfusion and coronary artery reocclusion are associated with increased morbidity and mortality.67 Ongoing thrombin formation during thrombolysis, even in the presence of intravenous heparin therapy, is a significant predisposing factor for reocclusion. 8, 9 Recently, a number of experimental studies investigating the direct thrombin inhibitor hirudin have shown promising results.10~12 148, 3.4%) compared with the heparin group (0 of 154). The overall stroke rate was 3.4% in the hirudin group and 1.3% in the heparin group. Other major bleeding occurred in five versus three patients and ventricular rupture occurred in three versus one patient in the hirudin and heparin groups, respectively. There were 19 in-hospital deaths, with 13 of them from the hirudin group.
Conclusions Although the number of patients was too small for a definite benefit-risk assessment, at the dosage tested, hirudin in combination with front-loaded alteplase and aspirin may be associated with an increased rate of intracranial hemorrhage. Our findings are consistent with the observations of the GUSTO-II and TIMI-9 trials, where higher doses of another recombinant hirudin were used. Therefore, the therapeutic range of hirudin as an adjunct to thrombolysis may be smaller than previously thought, and reappraisal of dose finding should be considered. (Circulation. 1994; 90:1638 -1642 Key Words * hirudin * thrombolysis * hemorrhage clinical trials
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Clinical phase II studies with a nonsulfated recombinant hirudin, HBW 023 (hereafter referred to as hirudin), in conjunction with recombinant tissue-type plasminogen activator (rTPA) in patients with acute myocardial infarction have identified a hirudin dosage associated with a high rate of early, complete, and sustained coronary artery patency and a low incidence of reocclusion.13"4 In these studies, no increased frequency of adverse events, and in particular, no intracranial bleeding, was observed. Similar results have recently been reported from a pilot study with another recombinant hirudin.15
The r-Hirudin for Improvement of Thrombolysis phase III study (HIT-IIl) compared hirudin with heparin as adjuncts to thrombolysis in patients with AMI to investigate the effects of hirudin therapy on mortality, reinfarction, and major bleeding. The pilot part of the study was designed to gather further information on hirudin in regard to safety and efficacy in 1000 patients from German hospitals, whereas in the main phase of the trial, it was planned to include 7000 patients treated with either rTPA or streptokinase from many international institutions. Due to an increased frequency of major bleeding events, the study was terminated prematurely after the inclusion of 302 patients. The preliminary results as of July 21, 1994, are presented in the following report.
Methods
The study was a prospective, randomized, double-blind multicenter trial in male and female patients with AMI and age above 18 years. The study protocol was approved by the Ethics Committee of the University of Gottingen and by the relevant institutional review boards of the participating centers. Patients with chest pain indicative of myocardial infarction with onset of symptoms within 6 hours were eligible if none of the established contraindications to thrombolysis or evidence of renal insufficiency was present. All patients gave informed consent.
Treatment Protocol
Patients fulfilling inclusion and exclusion criteria were randomized by the investigator telephoning a 24-hour service. The investigator was given the number of a treatment pack containing the trial medication for the patient.
All patients were to receive acetylsalicylic acid (ASA) with an initial dose of 250 mg PO. Then, each patient was given a bolus of either hirudin (0.4 mg/kg body wt) or heparin (70 IU/kg body wt). The yeast-derived recombinant [Leul, Thr2] 
Baseline Characteristics
The major baseline characteristics are depicted in Table 1 . Groups were comparable with respect to age, sex, and weight as well as systolic blood pressure and heart rate. In the majority of patients, treatment was started within 3 hours after onset of symptoms. The patients included into this study were not at "low risk," with 23% of patients >70 years old and 40% of patients with anterior AMI. However, the distribution of highrisk patients was similar in the two groups.
Mortality
During the in-hospital/observation period, 19 deaths were reported: 13 of 148 (8.8%) in the hirudin group and 6 of 154 (3.9%) in the heparin group (P=.1; Table  2 ). Thirty-day follow-up was incomplete at the time of this report.
There were nine cardiac deaths (6.1%) in the hirudin group, three of which were due to cardiac rupture. Four additional deaths in the hirudin group were due to hemorrhagic stroke (2.7%). In the heparin group, five deaths were due to cardiac causes (3.2%), one of which was a cardiac rupture. One patient had a fatal ischemic stroke (0.6%). Cerebrovascular Accidents There were five strokes in the hirudin group, four of them hemorrhagic strokes confirmed by computed tomography or autopsy and one classified as hemorrhagic because of clinical symptoms. Four of these events were fatal (see above). In the heparin group, two ischemic strokes occurred, one of which was fatal. Thus, the overall stroke rate was 3.4% in the hirudin group and 1.3% in the heparin group (P=.27). All hemorrhagic strokes occurred within 24 hours (5, 6, 6.5, 13, and 23 hours from treatment onset), whereas the ischemic strokes occurred on days 2 and 17. Major Bleeding Other Than Stroke There were eight other major bleeding events (Table  3) , five of which occurred in the hirudin group (3.4%) and three in the heparin group (1.9%). In five patients of the hirudin group, spontaneous gastrointestinal bleeding occurred. In the heparin group, one genitourinary bleeding, one hematoma necessitating transfusion, and one major puncture site bleeding were observed. aPTT Baseline median aPTT values in patients with bleeding events were comparable to those without bleeding 
Discussion
The HIT-III trial is the third phase III study after TIMI-9 and GUSTO-Il that compares heparin with hirudin as antithrombin adjuncts to thrombolysis in AMI. Although in HIT-Ill a different hirudin was used, the basic features of the three trials are quite similar; therefore, stopping both TIMI-9 and GUSTO-II for safety reasons 4 weeks after enrollment into HIT-Ill had begun caused major concern for safety for the HIT-Ill trial as well. Both the Safety Committee and the Steering Committee decided to continue enrollment because the bolus dose was substantially smaller (0.4 versus 0.6 mg/kg body wt) and the infusion rate was lower (0.15 versus 0.2 mg . kg`1 h-1) than in GUSTO-Il and TIMI-9. As an additional safeguard, an amendment to the study protocol was made as detailed above, and the Safety Committee was prompted to reassess safety after inclusion of every 100 patients. Furthermore, the Safety Committee was immediately notified of all cases of stroke. This extremely close safety monitoring turned out to be adequate since after inclusion of 300 patients, recruitment was terminated because of an unexpectedly In the heparin group, an increased bleeding rate was not observed, which may be due to weight-adjusted dosing and further adjustment for aPTT values of 2.0 to 3.5 times baseline. From the relatively small total number of patients with major bleeding in this trial, the impact of aPTT as an indicator of risk cannot be assessed adequately; however, there was a trend to higher aPTT in patients who were treated with hirudin and had a major bleeding event (Table 4) . At least for the prevention of intracranial hemorrhage, aPTT determinations would be of limited value, since three of these events were clinically manifest within 6 hours from treatment onset, and the other two occurred after 13 and 23 hours, respectively.
Even though the safety findings from HIT-III are not strictly conclusive on their own, the consistent observation of high rates of life-threatening bleeding in three independent trials with two hirudins and two different fibrinolytics raises important questions. Apart from issues regarding patient selection (age, comorbidity), the combination of hirudin and thrombolysis per se might increase the risk of bleeding via potentiating effects on fibrinolysis and/or hemostasis mechanisms. On the other hand, it may be simply a dosing problem that was not identified in phase II studies. Similar observed bleeding rates with significantly lower doses of hirudin in the HIT-III trial than in the GUSTO II and TIMI 9 trials point to a therapeutic range narrower than previously thought, at least in combination with thrombolytics. The definition of a hirudin regimen that is more efficacious than heparin and at least as safe might need reappraisal of the drug by another phase II trial.
